safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)10.30895/2312-7821-2020-8-3-160-162safetyrisk-197Research ArticleАКТУАЛЬНАЯ ИНФОРМАЦИЯRELEVANT INFORMATIONБезопасность применения ремдесивира и тоцилизумаба при лечении COVID-19Safety of Remdesivir and Tocilizumab in COVID-19 Treatmenthttps://orcid.org/0000-0001-5594-4859ТаубэАлександра АльбертовнаTaubeAlexandra A.

канд. фарм. наук

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

Cand. Sci. (Pharm.). 

8/2 Petrovsky Blvd, Moscow 127051

https://orcid.org/0000-0003-2665-796XКазаковАлександр СергеевичKazakovAlexandr S.

канд. мед. наук

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

Cand. Sci. (Med.). 

8/2 Petrovsky Blvd, Moscow 127051

kazakovas@expmed.ruhttps://orcid.org/0000-0001-9662-3701ДармостуковаМария АндреевнаDarmostukovaMarya A.

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

8/2 Petrovsky Blvd, Moscow 127051

darmostukova@expmed.ruhttps://orcid.org/0000-0002-9514-6322ВельцНаталия ЮрьевнаVeltsNatalya Yu.

канд. биол. наук, доцент

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

Cand. Sci. (Pharm.), Associate Professor

8/2 Petrovsky Blvd, Moscow 127051

velts@expmed.ruhttps://orcid.org/0000-0002-2888-5993ШубниковаЕлена ВладимировнаShubnikovaElena V.

канд. мед. наук

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

Cand. Sci. (Med.). 

8/2 Petrovsky Blvd, Moscow 127051

shubnikovaev@expmed.ruhttps://orcid.org/0000-0002-4647-977XАляутдинРенад НиколаевичAlyautdinRenad N.

д-р мед. наук, профессор

Петровский бульвар, д. 8, стр. 2, Москва, 127051, Российская Федерация

Dr. Sci. (Med.), Professor

8/2 Petrovsky Blvd, Moscow 127051

alyautdin@expmed.ruФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииРоссияScientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of RussiaRussian Federation20200709202083160162Copyright © Таубэ А.А., Казаков А.С., Дармостукова М.А., Вельц Н.Ю., Шубникова Е.В., Аляутдин Р.Н., 20202020Таубэ А.А., Казаков А.С., Дармостукова М.А., Вельц Н.Ю., Шубникова Е.В., Аляутдин Р.Н.Taube A.A., Kazakov A.S., Darmostukova M.A., Velts N.Y., Shubnikova E.V., Alyautdin R.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/197

При лечении пациентов, инфицированных SARS-CoV-2, важной задачей является проведение эффективной патогенетической и симптоматической терапии до развития угрожающих жизни осложнений, таких как пневмония, острый респираторный дистресс-синдром, сепсис. В настоящее время в схемах лечения COVID-19 широко используют ремдесивир и тоцилизумаб, однако сведений о безопасности данных препаратов недостаточно. В связи с этим экспертами Управления экспертизы безопасности лекарственных средств ФГБУ «НЦЭСМП» Минздрава России был проведен анализ нежелательных реакций при применении ремдесивира и тоцилизумаба по информации глобальной базы данных нежелательных реакций VigiBase (по состоянию на 27 августа 2020 г.).

An important part of treating patients infected with SARS-CoV-2 is to ensure effective pathogenetic and symptomatic therapy before life-threatening complications, such as pneumonia, acute respiratory distress syndrome, or sepsis begin to develop. Current COVID-19 treatment protocols often use remdesivir and tocilizumab, though safety data on these drugs are insufficient. Therefore, experts of the Centre for Evaluation of Medicinal Products’ Safety of the Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation studied adverse reactions to remdesivir and tocilizumab, which are registered in the VigiBase (as of August 27, 2020), the global database of individual case safety reports.

ремдесивиртоцилизумабCOVID-19нежелательные реакциипрофиль безопасностиremdesivirtocilizumabCOVID-19adverse drug reactionssafety profileReferencesGuaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9Favalli EG, Caporali R. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Lancet Rheumatol. 2020;2(8):e448–e449. https://doi.org/10.1016/S2665-9913(20)30185-5Favalli EG, Caporali R. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Lancet Rheumatol. 2020;2(8):e448–e449. https://doi.org/10.1016/S2665-9913(20)30185-5Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164. https://doi.org/10.1186/s12967-020-02339-3Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164. https://doi.org/10.1186/s12967-020-02339-3Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–8. https://doi.org/10.1016/j.dsx.2020.05.018Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–8. https://doi.org/10.1016/j.dsx.2020.05.018Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. https://doi.org/10.1038/s41467-019-13940-6Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. https://doi.org/10.1038/s41467-019-13940-6Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020;383:10.1056/NEJMc2022236#sa5. https://doi.org/10.1056/NEJMc2022236Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020;383:10.1056/NEJMc2022236#sa5. https://doi.org/10.1056/NEJMc2022236Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, at al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, at al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020-4-14. https://doi.org/10.7573/dic.2020-4-14Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020-4-14. https://doi.org/10.7573/dic.2020-4-14Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo. 2020;34(3 Suppl):1597–1602. https://doi.org/10.21873/invivo.11949Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo. 2020;34(3 Suppl):1597–1602. https://doi.org/10.21873/invivo.11949Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5. https://doi.org/10.1073/pnas.2005615117Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5. https://doi.org/10.1073/pnas.2005615117Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3

The authors declare that there are no conflicts of interest present.